Vanda Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Vanda Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- VNDA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001347178
Board of directors
-
Anne Sempowski Ward · DirectorSince 2023
-
Charles Cliff Duncan · DirectorSince 2026
-
Mihael Hristos Polymeropoulos · Director · President and CEOSince 2023
-
Phaedra Chrousos · DirectorSince 2023
-
Richard W. Dugan · DirectorSince 2023
-
Stephen Ray Mitchell · DirectorSince 2023
-
Tage Honore · DirectorSince 2023
Chief executives
Mihael Hristos Polymeropoulos
· President and CEO
Dates unknown
Board connections
1 of this board's directors also sit on 1 other board.
- via Anne Sempowski Ward
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $2,824,885
- 6 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 4, 2026 | McGuire Daniel Patrick Officer (SVP, GC and Secretary) | Grant or award | +80,000 | — | — |
| Jun 4, 2026 | Phaedra Chrousos Director | Grant or award | +41,600 | — | — |
| Jun 4, 2026 | Charles Cliff Duncan Director | Grant or award | +41,600 | — | — |
| Jun 4, 2026 | Richard W. Dugan Director | Grant or award | +41,600 | — | — |
| Jun 4, 2026 | Anne Sempowski Ward Director | Grant or award | +41,600 | — | — |
| Jun 4, 2026 | Tage Honore Director | Grant or award | +41,600 | — | — |
| Jun 4, 2026 | Stephen Ray Mitchell Director | Grant or award | +41,600 | — | — |
| May 18, 2026 | Stephen Ray Mitchell Director | Gift | −25,836 | — | — |
| Apr 22, 2026 | Charles Cliff Duncan Director | Grant or award | +57,101 | — | — |
| Mar 2, 2026 | Williams Timothy Officer (SVP & General Counsel) | Open-market sale | −42,434 | $8.27 | $350,929 |
| Mar 2, 2026 | Moran Kevin Patrick Officer (SVP, CFO & Treasurer) | Open-market sale | −42,442 | $8.27 | $350,995 |
| Mar 2, 2026 | Wijkstrom Joakim Officer (SVP, Chief Marketing Officer) | Open-market sale | −30,800 | $8.27 | $254,716 |
| Mar 2, 2026 | Mihael Hristos Polymeropoulos Director, Officer (President and CEO), Chairman of the Board | Open-market sale | −156,235 | $8.17 | $1,276,440 |
| Mar 2, 2026 | Birznieks Gunther Officer (SVP, Business Development) | Open-market sale | −42,431 | $8.27 | $350,904 |
| Feb 23, 2026 | Tage Honore Director | Open-market sale | −30,000 | $8.03 | $240,900 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.